SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Regeneron Highlights Hematology Program Data at ASH

Regeneron said it highlighted new data across its malignant and classical hematology programs at the American Society of Hematology meeting. The body begins to reference a trial analysis but is truncated.

REGN

Story updates

12:08:23 PM UTC
SquawkNews
Primary analysis from a potentially pivotal trial of Ordspono (odronextamab) in patients with R/R ma

Related stories